In patients living with HIV infection with hepatitis C (HCV) is common. HIV/HCV co-infection results in more rapid liver fibrosis progression than HCV alone and end-stage liver disease is a major cause of morbidity and mortality in co-infected patients. Historically, treatment outcomes with interferon based therapy in this group have been poor but with the advent of directly acting antiviral (DAA) drugs for HCV, rates of cure have improved dramatically. This article reviews recent evidence on the treatment of HCV in co-infected patients including the efficacy of new regimens and information on drug-drug interactions between DAAs and antiretroviral therapy. We also discuss the relationship between the pathogenesis of HIV and HCV infections, the treatment of acute hepatitis C and the current debate regarding the cost-effectiveness and affordability of DAAs.
Introduction
In the combination antiretroviral therapy (cART) era, life expectancy for people living with HIV infection has improved such that HIV is a manageable, chronic disease [1] . In addition, with the development of new ART drugs and fixed dose combinations, patients with HIV can expect a low pill burden and improved tolerability.
Whilst great strides have been made in the management of HIV, it is now essential that HIV physicians turn their attention to a problem which continues to cause serious illness and death in patients living with HIV infection; that of hepatitis C (HCV)/HIV co-infection.
Co-infection with HIV and HCV is common. In Europe and the United States, up to a third of patients living with HIV infection are co-infected with HCV [2] . In the cART era, liver disease is the main cause of non-AIDS death in HIV-infected individuals; HCV co-infection is responsible for 90% of deaths in HIV positive patients with end stage liver disease [1] [2] [3] [4] .
This excess mortality is partly explained by the accelerated trajectory of liver disease in HIV/HCV coinfection. Co-infected individuals are more likely to develop chronic HCV following acute infection [5] and have more rapidly progressive liver disease, in terms of fibrosis progression, risk of decompensation and liver cancer development once cirrhotic [6, 7] . Transplant outcomes in HIV/HCV are 'prohibitively' poor with lower survival rates in HIV/HCV co-infection than HCV mono-infection, driven by HCV recurrence [8] .
Historically, patients with HIV/HCV co-infection experience significantly poorer treatment outcomes compared with those of HCV mono-infection. However, with the advent of new therapies, the efficacy and tolerability of HCV treatment has been transformed. Directly acting antivirals (DAAs), which act on various replication steps in the life cycle of HCV, obviate the requirement for pegylated interferon and long treatment duration. In contrast to previous treatment, new and emerging therapies for HCV provide simplified regimens and show comparable efficacy in those patients with HIV/HCV co-infection. The current recommendation of both American and European guidelines is that HIV/ HCV co-infection should not be managed differently from HCV mono-infection, confirming that patients with HIV should no longer be considered a 'special population' in HCV [9, 10] . Clinicians managing individuals with HIV/HCV co-infection need to be fully aware of the changing landscape, in order that their patients may benefit from what is tantamount to a revolution in HCV treatment.
This review was written following a comprehensive literature search for all studies on HIV/HCV co-infection; to ensure inclusion of relevant current data, the scope of the search included recent international HIV and hepatology conferences. We aim to summarize the evidence for treating HIV/HCV co-infected individuals with DAAs, selecting the most clinically important data. In particular we will focus on several key recent studies in the field of co-infection and highlight that timely assessment and treatment of HCV in co-infection is essential to prevent excess morbidity and mortality in this group.
Need to treat: impact of HIV on hepatitis C virus
In the past, a minority of patients with HIV/HCV co-infection have been treated [11, 12] . Several reasons can contribute: patient factors including comorbidities, substance misuse and patient preference, physician factors including preconceptions and low referral rates to specialist liver services, and treatment factors including poor treatment response rates and significant side-effect profile [13, 14] .
It is important that patients with HIV/HCVare identified and assessed for treatment. Fibrosis progression is more rapid in HCV/HIV; in HCV mono-infection; an algorithm based on analysis of multiple cohort studies estimates that approximately 6% of patients will progress to hepatic decompensation within 20 years of acquiring HCV [15] , whilst four out of 15 men with HIVand acute HCV developed decompensated cirrhosis between 17 months and 6 years after acquiring HCV infection [16] . There is a wealth of data showing that co-infected individuals experience rapid fibrosis progression and have a higher risk of cirrhosis and decompensated liver disease than HCV mono-infection [5, [17] [18] [19] .
The majority of studies reporting rapid fibrosis progression in HIV/HCVare from the pre-ARTera. There is some evidence that fibrosis progression can be ameliorated by effective cART [20] . Patients with HIV/HCV co-infection on cART have stable HCV RNA levels and lower rates of decompensation compared with those not on cART [12, 21] . Conversely, other studies have found that effective cART does not protect against rapid fibrosis progression or on the risk of decompensation in patients with advanced fibrosis or cirrhosis [7, 19, 22] .
The rapid fibrosis progression seen in HIV/HCV results in an increase in cirrhosis and consequently, hepatocellular carcinoma (HCC) in HIV/HCV co-infected patients. HCC in this group carries a high mortality [11, 23] . In both American and European cohorts of patients with HIV infection, HIV/HCV co-infection is the most important risk factor for HCC [11, 24] .
The need for HCV treatment in patients with HIV/HCV is best demonstrated by comparing the outcomes of those HIV/HCV patients who achieve a sustained virological response (SVR) with those who do not. HIV/HCV patients who achieve an SVR have dramatically lower rates of liver-related death, HCC and all cause mortality [25, 26] . The reduction in decompensation and mortality is also seen in cirrhotic patients who achieve an SVR [26, 27] .
Need to treat: the impact of hepatitis C virus on HIV
It is accepted that the presence of HIV infection has an adverse impact on the natural history of HCV infection. Conversely, the consensus has been that HCV has no direct impact on the natural history of HIV infection. This was mainly based on studies from the pre-ART era [28, 29] . However, a number of more recent investigations suggest that co-infection with HCV may have an impact on the natural history of HIV infection and overall mortality.
A meta-analysis of patients initiating cART found that although HIV viral suppression was unaffected, patients with HIV/HCV experienced a smaller rise in CD4 þ cell count on ART compared with HIV mono-infected patients [30] . A recent cohort study of over 9000 individuals with HIV infection found that in the cART era, HCV co-infection not only increases the risk of liver mortality but also increased the risk of HIV and/or AIDS-related mortality. This persisted after controlling for risk group and was also independent of HIV RNA level as HIV/HCV co-infected individuals were equally likely to achieve undetectable HIV viraemia after initiating ART [31] . As the authors comment, this suggests that HCV has some impact on HIV disease progression independent of liver fibrosis. Another recent large cohort study found that whilst overall mortality had declined from the pre-cART to the cART era in HIV mono-infected persons, no such decline was seen in HCV co-infected patients. This was true for liver-related death but also for AIDS-related death and non-liver, non-AIDS death including cardiovascular disease and non-AIDS malignancies [25] . Data from the same cohort found that an SVR in HIV/HCV co-infected patients decreases non-liver and also non-liver, non-AIDS mortality [25] .
Need to treat: acute hepatitis C virus in HIV
The incidence of acute HCVamongst HIV-positive MSM has increased dramatically over the past 10 years, with outbreaks reported in Europe, the United States and Australia [32] [33] [34] . Data from multiple European cohorts of HIV-positive MSM show an increase in HCV incidence from 8.1 per 1000 person-years in 1995 to between 23.4 and 51.1 per 1000 person-years in 2007 [35] .
Specific risk factors for acquiring acute HCV in HIVpositive men have been identified including receptive anal sex, concomitant genital ulceration and other highrisk practices including fisting and recreational drug use [36, 37] . Acute HCV has been reported amongst HIV negative men with similar risk factors but the incidence is higher in the context of HIV infection [38, 39] . Treatment with pegylated interferon and RIB during the acute phase of HCV has a substantially higher SVR rate than treating chronic HCV in HIV with SVR rates of over 80% if treated within 12 weeks. Early identification and treatment have led to increased cure rates [40, 41] ; in the Swiss HIV cohort, treatment of HCV in the acute phase increased from 22% pre-2006 to 91% post-2006, SVR rates in acute HCV/HIV were 78% compared with 29% in chronic HCV [42] .
In most cases those with acute HCV will have minimal liver disease so the rationale for treatment could be viewed as 'treatment as prevention' rather than treatment for the individual. Treatment as prevention is a recognized indication for initiating treatment of HIV infection [43] . Modelling of the treatment of HCV as prevention in actively injecting drug users shows that the scale up of treatment rates by 15-fold could half HCV prevalence within 15 years [44] . However, reinfection rates in this group are relatively low [45] . HIV/HCV positive MSM are a relatively small population and are well connected to regular healthcare and access to HCV testing and treatment [46] . Thus, this group could be well suited to a treatment as prevention strategy and guidelines recommend initiation of treatment in HCV-infected MSM for this reason [9] . Unfortunately, reinfection rates after clearance are high with a cumulative reinfection rate of 33% in 2 years in an Amsterdam cohort and 25% in 2 years in a London cohort [44, 47] . It is these reinfection rates, coupled with the current high cost of DAA therapy, which could potentially present a barrier to treatment as an effective HCV prevention strategy [48] .
Evolution of treatment for hepatitis C virus
Historically, all treatment for HCV has been based around the combination of pegylated interferon and RIB (peg IFN/RIB). Patients with HIV/HCV have experienced lower SVR rates than HCV mono-infected patients with SVR rates of only 36-38% for genotype 1 (G1) and 53-72% for genotype 2 (G2) and 3 (G3) in HIV/HCV coinfection compared with respective rates of 40-60% (G1) and 70-80% (G2/3) in HCV mono-infection [49] [50] [51] [52] .
The next step in the evolution of HCV treatment has been the development of the first generation protease inhibitors, which represented the first DAAs, which as the name suggests, act directly on sites within the HCV virus. Telaprevir and boceprevir were used as 'triple therapy' with peg IFN/RIB for the treatment of G1. In HCV mono-infected patients, treatment with telaprevir-or boceprevir-based triple therapy resulted in SVR rates of 75 and 63%, respectively, in treatment-naive patients with G1 HCV [53, 54] . In HIV/HCV co-infection, SVR rates with telaprevir or boceprevir were 63 and 74%, respectively, higher than previously seen [55, 56] . However, drug-drug interactions (DDIs), high pill burden and high rates of adverse events mean that these drugs are no longer recommended for either HCV mono-infection or HIV/HCV co-infection [9, 57] .
Current recommended treatments for hepatitis C virus
Over the past few years a plethora of trials evaluating an array of DAAs have occurred in HCV mono-and coinfection (Table 1 ). There are several classes of DAA which have differing genotypic activity, potency and barriers to resistance and it is these parameters which inform which drugs can be combined to form a robust and potent regimen ( Fig. 1 ).
In the following section we will look at the data behind the 'headline' drug regimens which are recommended by European and American guidelines for the treatment of HCV or are in the final stages of regulatory approval. For each regimen it is important to consider the activity against each genotype, the risk of resistance and the role of RIB. For the co-infected group, the question of DDIs, is an area that still merits special attention ( Table 2 ). Whilst specialist knowledge of both cART and DAA drugs is required to oversee HCV treatment in patients with co-infection, resources such as the Liverpool University HIV and HEP Drug Interactions website are invaluable [58, 59] .
Sofosbuvir and RIB
Sofosbuvir (SOF) is the first nucleotide NS5B polymerase inhibitor to be licensed for the treatment of HCV and has pangenotypic activity, few side-effects and results in high SVR rates [60, 61] .
The PHOTON-1 phase 3 study in HIV/HCV coinfected patients treated treatment-naive G1 patients with 24 weeks of SOF/RIB, treatment-naive G2 and G3 for 12 weeks and treatment-experienced G2 and G3 for 24 weeks. This resulted in SVR rates among treatmentnaive patients with G1, 2 and 3 of 76, 88 and 67%, respectively. Among treatment-experienced pts with G2 and 3, SVR rates were 92 and 94%, respectively [62] . The most common adverse events were fatigue, insomnia, nausea and headache. Among patients with treatmentexperienced G3, SVR rates were 67% in those treated for 12 weeks and 94% in those treated for 24 weeks. This mirrors the findings of the VALENCE trial in HCV mono-infection, which demonstrated higher SVR rates in G3 for those treated for 24 weeks than 12 weeks [63] .
Recently, the PHOTON-2 study has demonstrated that in treatment-naive patients, 24 weeks of SOF/RIB for G1, 3 and 4 and 12 weeks for G2 achieves SVR rates of 84-89% in HIV/HCV co-infected individuals [64] .
SOF is not metabolized through CYP450 but is a substrate for P-glycoprotein. A cohort study of healthy volunteers studied the interaction of SOF with emtricitabine (FTC), tenofovir (TDF), efavirenz (EFZ), raltegravir (RAL), darunavir with ritonavir (DRV/RTV) and rilpiverine (RPV). The most significant findings were of a decrease in RAL exposure and an increase in TDF exposure. Neither was deemed clinically significant [65] .
In a study of patients with HIV/HCV, there were no significant DDIs between SOF and EFZ, FTC, TDF, RAL, zidovudine (ZDV), lamivudine (3TC), atazanavir (ATZ), RTVor DRV [66] . No significant interactions are predicted between SOF and other nucleoside reverse transcriptase inhibitors, dolutegravir, cobicistat-boosted elvitegravir or maraviroc [67] .
European and American guidelines now only recommend SOF/RIB for the treatment of G2 HCV or 24 weeks of treatment for those with G3 who are intolerant to peg-IFN [9, 10] .
Sofosbuvir/daclatasvir
Daclatasvir (DAC) was the first NS5A inhibitor to be developed. The NS5A proteins have numerous functions including roles in HCV viral replication and assembly [68] . In vitro, NS5A inhibitors have moderate to high potency across all genotypes but specific combinations have been studied only in specific genotypes [68, 69] .
The combination of SOF/DAC in patients with HIV/ HCV was investigated in the ALLY-2 study. Patients had any genotype HCV (non-G1 capped at 20%) and HIV infection. Treatment-naive patients were randomized to Directly acting antiviral drugs for treatment of HIV/hepatitis C co-infection Childs et al. 979 Interactions have been studied with ritonavir-boosted protease inhibitors. Where these drugs require dose adjustments, theoretical interactions may also occur with cobicistat-boosted protease inhibitors.
receive 8 or 12 weeks of SOF/DAC and treatmentexperienced patients received 12 weeks. There were no restrictions on cART regime; nonnucleoside, protease inhibitor and integrase inhibitor based regimens were included [70] .
SVR rates were 96-98% in both groups receiving 12 weeks of treatment but only 76% in the 8-week group.
There was no significant impact of baseline HCV RNA, race or cirrhosis on SVR rates within the 12-week treatment groups. The lower SVR rates seen in the 8-week arm were at odds with the results from the ION-3 study of SOF with ledipasvir (LDV) in patients with HCV mono-infection where response rates after 8 weeks of treatment did not differ from the 12-week response rates (93 and 94%). The ALLY-2 authors recommend that 12 weeks of SOF/DAC be used for patients with HIV/ HCV co-infection and sought to understand the reasons behind the lower SVR rates in the 8-week arm. SVR rates in the 8-week arm differed by baseline HCV RNA; 100% SVR in those with less than 2 million IU/ml and 62% SVR in those with above 2 million IU/ml. Seven of 10 of those who relapsed in the 8-week group were receiving DRV/r and had their DAC dose reduced to 30 mg. This dose reduction was based on earlier pharmacokinetic work. DAC is a substrate for CYP3A4 and studies in healthy volunteers show that DAC exposure is decreased by co-administration with EFZ and increased by co-administration with ATZ/RTV [71] . Therefore the usual dose of 60 mg daily of DAC is increased to 90 mg when co-administered with EFZ and decreased to 30 mg when co-administered with ATZ/ RTV. This result was extrapolated to use the same dose reduction when co-administering DAC with DRV/RTV.
However, recent data show that ATZ/RTV increases the AUC of DAC by two-fold but this effect was less pronounced with DRV (40% increase) and lopinavir (LPV) (15% increase). Boosting the ATZ or DRV with cobicistat instead of ritonavir had the same effect on DAC levels. The authors recommend that no dose adjustment of DAC is required with DRV or LPV [72] .
Although the data from ALLY-2 are extremely promising, the missing information is on SOF/DAC for G3 in coinfection. Only 6% of patients in the ALLY-2 study were G3. In HCV mono-infection, study A1444040 revealed SVR rates of 89% with 24 weeks SOF/DAC in G3 compared with 98% in G1. The ALLY-3 study in HCV mono-infection specifically looked at the impact of 12 weeks of SOF/DAC without RIB in patients with G3 infection. Whilst the overall SVR rate was 90% in treatment-naive patients, the SVR rate in cirrhotic patients was considerably lower; 59% in treatment naive and 63% in treatment experienced [73, 74] . So whilst SOF/DAC is probably the most efficacious available interferon-free treatment for G3, more data are warranted in the context of co-infection. Clinicians treating cirrhotic patients with this combination may wish to consider the inclusion of RIB.
As a class, NS5A drugs have a low genetic barrier to resistance. The L31M/F and Y93H resistance associated mutations (RAVs) are associated with relapse or viral breakthrough. The Y93H RAV confers 24-fold resistance to DAC and in a Japanese study of G1b patients receiving DAC and asuneprevir, half of patients with this mutation at baseline failed treatment although the other half carrying this mutation did achieve an SVR. Patients who failed treatment had both NS5A and NS3 protease mutations detectable at the end of treatment but only the former were still detectable 1 year post treatment [75] .
SOF/DAC is recommended by European guidelines for the treatment of G1-G6 HCV. Patients with G3 and cirrhosis should be treated for 24 weeks [9, 57] . DAC is not currently available in the United States.
Sofosbuvir/ledipasvir
LDV is an NS5A replication complex inhibitor which has activity against HCV G1a and 1b, G4 and G5 but lower activity against G2 and 3 in vitro [68] . It is available as Harvoni, a once daily fixed dose combination with SOF (90 mg LDV, 400 mg SOF).
An investigator-initiated open-label study tested the fixed dose combination of SOF/LDV in 50 patients with HIV/ HCV G1, the majority were HCV G1a. One group were on truvada (TVD)-based ART, the other group not on ART. Patients with cirrhosis were not included. SVR 12 rates were 98% overall [76] .
ION-4 is a single-arm phase 3 study of SOF/LDV for 12 weeks in patients with well controlled HIV infection and HCV genotype 1 or 4 (2% of study participants). Permitted ART regimens were TDF/FTC with EFV, RPV or RAL, 20% of the study population had compensated cirrhosis. The overall SVR rate was 96% but black patients had a significantly lower SVR rate of 90%, compared with 99% in non-black patients. This was not seen in the larger ION cohort of HCV monoinfected patients treated with SOF/LDV and the investigators were unable to explain this lower response rate [77] .
With the exception of the apparently lower SVR rates in black patients, the SVR rates seen in co-infection reflect those seen in mono-infection, SOF/LDV has achieved SVR rates of 95-100% in HCV monoinfected treatment-naive patients, adding RIB or extending treatment from 8 to 12 weeks did not have any impact [78, 79] . Treatment-experienced patients, including those with cirrhosis achieve SVR rates of 94-100 with 12-24 weeks of this combination with or without RIB [80] . In a study of patients with G4 and G5, where 25% of the population were cirrhotic, SVR rates of 93 and 95% were seen after 12 weeks of SOF/ LDV [81] .
The fixed-dose combination of SOF/LDV causes a modest increase in tenofovir levels of 1.3-1.8 fold in healthy volunteers. This was not felt to be clinically significant. Similarly there was no impact on RAL, EFV or RPV [82] .
A randomized pharmacokinetic study has raised concern about the co-administration of TVD, boosted protease inhibitors and SOF/LDV. Four groups of healthy volunteers were randomized to receive TVD plus either ATZ/RTV or DRV/RTV either with or without coadministration of SOF/LDV. TDF concentrations increased 38-64% when given with SOF/LDV with either of the boosted protease inhibitors compared with when given with the boosted protease inhibitor alone [83] . Although these effects were not deemed clinically significant in this trial, European and American guidelines recommend that TVD should not be used in combination with a boosted protease inhibitor and SOF/LDV where possible and if it is used, that renal monitoring for evidence of TDF toxicity is indicated [10] .
As with DAC, LDV has a low genetic barrier to resistance. Of patients enrolled in clinical trials of LDV-based combinations not including SOF, 99% of those who did not achieve SVR developed NS5A RAVS and these persisted in the majority of patients beyond 96 weeks of follow-up [84] . The presence of RAVS will also need to be considered when retreating patients who have not achieved an SVR. Retreatment of patients who had not responded to 8 or 12 weeks of SOF/LDV with 24 weeks of the same regimen showed an SVR rate of 71%. Only 50% of those with two or more baseline NS5a RAVS achieved SVR [85] .
SOF/LDV is recommended by both American and European guidelines for the treatment of G1, 4, 5 and 6 [9, 10] .
Simeprevir and peg interferon and RIB
The first generation protease inhibitors have been followed by the first generation second wave protease inhibitors which include simeprevir (SIM), asuneprevir and paritaprevir. These drugs have an improved sideeffect profile and more favourable dosing compared with the first wave protease inhibitors but a similar barrier to resistance [86] .
SIM is a NS3/4a protease inhibitor with activity against G1, 2 and G4-6 and can be used as triple therapy with peg IFN/RIB, when it is given for 12 weeks followed by 12-36 weeks of peg IFN/RIB alone. It can also be used as part of an interferon-free regimen in combination with SOF. It is one pill once a day and has fewer side-effects than earlier first generation protease inhibitors.
The combination of SIM with peg IFN/RIB in HIV/ HCV G1 patients was evaluated in a phase 3 open-label study. Overall SVR rates were 74%. Eighty-nine per cent of HCV treatment-naive patients and prior relapsers met the response-guided therapy criteria to receive shortened therapy of 24 weeks resulting in high SVR rates of 87% in this group [87] .
These SVR rates do not differ from the 80% SVR seen in HCV mono-infected G1 treatment-naive patients [88] . SVR rates in Genotype 4 HCV are 83% in treatmentnaive patients and 40% in prior null responders [89] .
Use of SIM is slightly complicated by the need to perform testing for the Q80K mutation in the NS3 protease, which is seen in those with G1a HCV. In the QUEST-1 study, patients with HCV G1a had almost 20% lower SVR rates than HCV G1b. At baseline the Q80K mutation was found in approximately one third of G1a patients. On the contrary, in the QUEST-2 study this mutation was infrequent and did not impact significantly on the SVR rate [88, 90] . In co-infected patients, SVR rates were 89% in G1b, 67% in G1a with Q80K and 72% in G1a without Q80K [87] .
SIM is a substrate for CYP3A and also inhibits the hepatic CYP1A29 enzymes. Neither EFZ nor a boosted protease inhibitor can be co-administered as EFZ decreases SIM levels and boosted protease inhibitors decrease SIM levels [91] . SIM can be safely co-administered with TDF, RAL and RPV [91] and no adverse interactions are predicted with other NRTIs, dolutegravir or maraviroc [92] .
European guidelines recommend that this combination is one option for patients with G1 (if G1a without Q80K) or G4 HCV. American guidelines do not recommend this combination [9, 10] .
Sofosbuvir/simeprevir
This combination has been in widespread use, particularly in North America. There are strong data in HCV monoinfection; the COSMOS study showed that HCV monoinfected patients achieved SVR rates of 90-94% with SOF/SIM. This was independent of fibrosis stage or previous treatment response and neither adding RIB nor increasing the duration of therapy from 12 to 24 weeks improved SVR rates [93] . The OPTIMIST-1 trial showed SVR rates of 97% with 12 weeks SIM/SOF; the Q80K mutation had no impact [94] . OPTIMIST-2 showed SVR rates of 83% in cirrhotic patients with 12 weeks SIM/SOF but there was a lower rate of 74% in patients with the Q80K; therefore, American guidelines recommend avoiding this regimen in cirrhotic patients with G1a and the Q80K mutation [9, 95] .
Data in HIV/HCV co-infection are much more limited but suggest no difference between mono-and co-infected patients. A real-life cohort study of SOF/SIM used in patients with advanced fibrosis showed SVR rates of 70% in HCV mono-infection and 76% in HIV/HCV co-infection [96] .
The combination of SOF/SIM is recommended by American and European guidelines for the treatment of G1 and G4 [9, 10] .
Abbvie 3D
The TURQUOISE-1 study randomized HIV/HCV G1 patients to be treated with the Abbvie 3D combination of the protease inhibitor paritaprevir (formerly ABT-450) boosted with ritonavir, the NS5A inhibitor ombitasvir, the nonnucleoside polymerase inhibitor dasabuvir and RIB for either 12 or 24 weeks. Patients were treatment naive or previous nonresponders to peg IFN/RIB, a fifth of the study population were cirrhotic. SVR rates in those treated with 12 weeks were 94%, those treated for 24 weeks had SVR rates of 91%. The regimen was well tolerated with no serious adverse events. The patients had well controlled HIV infection and were on ATZ-or RAL-based cART [97] .
These response rates do not differ from those seen in mono-infection. SAPPHIRE -1 reported SVR rates of 95% with 12 weeks of this regimen. In mono-infected patients with cirrhosis, those with G1a and a prior null response to treatment had lower SVR rates with 12 weeks of therapy compared with 24 weeks [98] . Paritaprevir, ritonavir, ombitasvir and RIB can also be used without dasabuvir for the treatment of G4 HCV. The combination is referred to as Abbvie 2D. The phase 2 PEARL-1 study randomized treatment-naive G4 patients to receive Abbvie 2D with or without RIB. SVR rates were 100% in the RIB group and 90% in the non-RIB group although this did not achieve statistical significance. All treatment-experienced patients received RIB and the SVR rate was 100% [99] .
As this combination contains ritonavir, which is a strong inhibitor of CYP3A, there are a number of DDIs to be considered. Levels of all substrates of CYP3A will be predictably increased as with any ritonavir-boosted regimen. If the Abbvie-3D combination is given to a patient with HIV infection on protease inhibitor containing cART, only the ritonavir in the 3D regimen is required. Paritaprevir is a substrate and inducer of CYP3A and an inhibitor of OATP [100] . Therefore levels of paritaprevir will be increased by ATZ. Studies in healthy volunteers showed that co-administration of 3D with ATZ resulted in a 94% increase in the AUC of paritaprevir and a 68% increase in trough levels of ATZ [101] . However, the combination was well tolerated and no dose adjustments are recommended. Co-administration of 3D with once daily DRV decreased the trough levels of darunavir by 48%, consequently American guidelines recommend that this combination should be avoided [9] . Co-administration of 3D with LPV/RTV is not recommended as the fixed dose combination of these medications results in a total daily dose of 300 mg ritonavir [101] .
The components of 3D also increase the exposure of substrates metabolized by UGT1A1 which results in overall increased exposure of RAL. However, pharmacokinetic studies in healthy volunteers showed no safety concerns and thus no dose adjustment is required. Co-administration with nonnucleoside reverse-transcriptase inhibitors resulted in increased exposure of RIL, which is associated with prolonged QT interval. There were increased neurological adverse effects with EFZ and elevation of hepatic enzymes. Hence co-administration with EFZ or RPV is not recommended [102] .
There are no significant interactions seen with 3D and TDF, FTC or RAL [102] .
European and American guidelines recommend this combination for G1 and G4 but stipulate that in patients with G1a and cirrhosis, 24 weeks of treatment is recommended [9, 10] .
Merck combinations
Grazoprevir [MK-5172] is a second generation NS3/4A protease inhibitor. Compared with the first generation and first generation, second wave protease inhibitors, it has pangenotypic activity and a high barrier to resistance. It is available as a once daily fixed dose combination with Elbasvir, an NS5A inhibitor.
The C-WORTHY trial was a phase 2 study that assessed the combination of grazoprevir and elbasvir with and without RIB in patients with treatment-naive G1. Unusually this trial enrolled both HCV mono-infected and HIV/HCV co-infected patients thus allowing for direct comparison. SVR rates in those treated for 12 weeks were 93-98% in HCV mono-infection and 87-97% in co-infection. SVR with RIB was 97%, without RIB was 87% although this difference was not statistically significant. Viral kinetics were similar in both groups, although in the highest viral load category there was a nonsignificant trend towards lower SVR in the HIV/HCV co-infected group. Co-infected patients were all on an cART combination of RAL and two nucleoside/nucleotide reverse transcriptase inhibitors. Significant adverse events were infrequent in both groups. The HCV mono-infected group was further randomized to receive either 8 or 12 weeks of grazoprevir, elbasvir with RIB or 12 weeks grazoprevir and elbasvir alone. There was no significant difference between SVR in the two 12-week groups with rates of 93% (RIB group) and 98% (no RIB) but the SVR in the 8-week group was lower at 80% [103] .
The C-EDGE phase 3 trial was a single-arm open label study using 12 weeks of grazoprevir and elbasvir without RIB in treatment-naive HIV/HCV co-infected patients with G1, 4 or 6. The overall SVR rate was 95% with no difference according to genotype or the presence of cirrhosis [104] .
Grazoprevir is a substrate of CYP3A and P-glycoprotein and a weak CYP3A inhibitor. Elbasvir is a substrate of CYP3A. EFZ decreases the AUC of grazoprevir by 84% in healthy volunteers [105] . LPV, ATZ and DRV all significantly increase grazoprevir exposure [106] . Therefore, EFZ and boosted protease inhibitors are not recommended for co-administration with this combination. In the C-WORTHY study, HIV/HCV patients were stable on RAL plus a nucleotide/side backbone. HIV viral suppression was maintained throughout treatment [103] . In the C-EDGE study, permitted cART regimens were TDF or abacavir plus lamivudine or FTC and either RAL, DOL or RIL [104] .
The once daily combination of grazoprevir and elbasvir is awaiting approval from the FDA for the treatment of Genotype 1, 4 and 6.
Access to new hepatitis C virus treatments
DAA therapy for HCV represents a quantum leap in terms of efficacy. The real obstacle to an HCV cure for all will be the affordability of these medications, which will limit universal access. SOF, for example, costs $1000 per pill, resulting in a cost of $84 000 per cure. The cost of treating 3.2 million Americans will therefore be 270 billion dollars, roughly 10% of the total U.S. healthcare budget [107] .
Although the cost of treatment is high, it must be remembered that the current and future economic burden of HCV is also high. All-cause mortality in chronic HCV RNA positive patients is three times that of patients without HCV [108] . Achieving SVR in patients with HIV/HCV decreases the 5-year risk of death or HCC 10-fold (D Dieterich, 2015, personal communication). The costs associated with HCV are projected to rise in the coming decades. Modelling of future outcomes of HCV in terms of prevalence of end-stage liver disease showed that although the peak of HCV prevalence has passed, the peak of the healthcare cost associated with HCV will occur between 2020 and 2030 [109] ; therefore, treating patients with moderate disease now should help reduce these projected future costs. For this reason, a number of studies have found that DAA treatment for HCV is cost effective, particularly for patients with cirrhosis [110] [111] [112] [113] .
In a world of limited resources, however, cost effectiveness per se will not guarantee that treatment is available. This was demonstrated by unusual events in the United Kingdom. The originator of the cost-effectiveness in healthcare model, the UK's National Institute for Clinical Excellence (NICE) ruled in February 2015 that SOF is cost effective and approved use of the drug. In the United Kingdom, the provider is the National Health Service (NHS). Despite receiving NICE approval, NHS England did not sanction use of the medication until the 10 June despite criticism from medical and patient groups in the intervening months. These unprecedented circumstances illustrate well the current problem with funding HCV treatment; the new treatments are cost-effective but may not be affordable.
As a consequence of the high cost of medications, it is unlikely that all individuals with HCV can expect immediate access to interferon-free regimens. The funding situation is dictated by the negotiations between pharmaceutical companies and the provider (or payee). These are nuanced and vary from country to country. Several factors may be used to stratify patients, for example the degree of fibrosis or previous treatment response. It may be that cases are prioritized so that only patients with advanced or severe fibrosis receive interferon-free combinations. This will defer costs but runs the risk of allowing fibrosis to progress, and will add the costs of ongoing fibrosis assessment. To maximize the efficaciousness of DAA regimens, guidelines recommend that HCV treatment should be delivered in a multidisciplinary team environment. Patients with ongoing alcohol or drug use should receive additional support and have access to harm reduction programmes [10, 114] .
In the United Kingdom, cost effectiveness is adjudicated by NICE and healthcare provided by the NHS. Elsewhere in Europe, for example in Italy, discussions occur on regional basis, and deals involving volume-based discounts are already happening. Gilead, the manufacturer of Harvoni, has committed to price concessions in France, Italy and Spain in return for a commitment by those nations on treating a large volume of patients [115] .
In the United States, cost is an issue between patients and their insurance providers. Some insurers have restricted which regimens can be prescribed or limited their use to those with advanced fibrosis. Those individuals without insurance have little chance of accessing treatment [116] .
In the coming years there will be a move to treat all patients with HCV. Recently updated American, European and injecting drug user guidelines recommend that all patients with HCV should be treated and that those with HIV/HCV co-infection be treated as a high priority group [9, 10, 114] . Treatment may be seen as a 'right', rather than a limited access delineated on somewhat artificial parameters, such as fibrosis.
In considering the costs of these treatments, HCV infection cannot be viewed in isolation. Rather the overall health and risk profile of an individual patient must be taken into consideration. Recent data demonstrate the importance of alcohol in the context of HCV infection.
In a large cohort study of all patients hospitalized in France between 2008 and 2012, patients with HCV were six times more likely to consume excess alcohol and the majority of liver-related morbidity in patients with HCV was in those with high alcohol consumption or another serious comorbidity for example renal disease or the metabolic syndrome. The author called into question the cost effectiveness of treating HCV with expensive DAAs as the progression of HCV in the absence of alcohol or comorbidities may be less rapid than previously reported [117] . This study highlights the requirement of physicians to focus on all aspects of liver health.
A final point to be considered is the cost of treating reinfection with HCV, which is likely to prove controversial and is particularly relevant in the context of HIV co-infection. In the past, treating HCV as quickly as possible after acquisition in patients with HIV was critical in order to capitalize on the higher SVR rates that were seen in the acute phase. However, with the advent of DAAs and predicted SVR rates of more than 90% in chronic HCV/HIV, this distinction is to all purposes redundant. In an environment where it is unclear whether those with HCV and mild fibrosis can be treated at all, providing multiple courses of an expensive treatment to a patient with ongoing high-risk behaviour and potential subsequent reinfection raises ethical considerations. Developing strategies and programmes to help individuals change this behaviour will need to be developed in tandem with the wider availability of DAA treatment.
The interactions between those paying for drugs and those marketing drugs are complex and subject to change depending on a number of factors. Whilst Gilead has committed to provide free drugs to the entire nation of Georgia, in an attempt to demonstrate that eradicating HCV from a whole country is possible [118] , clearly most nations cannot hope to benefit from this type of intervention. In other areas of the world treatment with new agents will initially be focused on those with the most severe liver disease. Over time however, and with the approval of greater numbers of drug combinations, the majority of those with HCV should gain access to treatment. On a population level, this will only be costeffective if delivered as part of a package that addresses all aspects of liver health, appropriate screening and a significant increase in treatment rates.
Summary
In the past, the majority of patients with HIV/HCV were not treated for HCV. The available treatments were difficult to tolerate, of long duration and unlikely to result in a cure.
Treatment for HCV has changed beyond recognition in the past 5 years. There are now a large number of DAAs that can be combined without interferon to give higher cure rates than previously possible. Patients with HIV/ HCV should no longer be considered a 'special population' as treatment outcomes and tolerability are comparable to HCV mono-infected patients.
DDIs add complexity to the management of HIV/HCV co-infected individuals and close co-operation between hepatologists and HIV care providers will become even more important. In the current era, HIV/HCV coinfected individuals finally have the chance to access highly effective HCV treatment. Guidelines recommend that they are treated as a priority group and the real challenge will be the timely identification and assessment of HIV/HCV co-infected patients for treatment. In patients with HIV/HCV, SVR translates to reductions in fibrosis progression, liver failure, HCC and death. This population who was previously characterized as a 'difficult to treat' population should now be viewed as a 'greatest benefit from treatment' population. It is vital that this group of patients, once poorly served, should benefit from the recent revolution in HCV treatment.
